Camp4 Therapeutics Corp. CAMP 深 滬
已收盤 10-31 16:00:00 美东时间
4.16
+0.130
+3.23%
華盛通- 最 高4.16
- 今 開4.00
- 成交量 4.40万股
- 最 低 3.78
- 昨 收 4.03
- 總市值 8387.02万
- 52周最高 12.26
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.305
- 委 比 -5.82%
- 總股本 2016.11万
- 歷史最高 12.30
- 量 比 0.52
- 振 幅 9.43%
- 歷史最低 0.40
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
10-31 20:10
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
Cantor Fitzgerald Initiates Coverage On Camp4 Therapeutics with Overweight Rating, Announces Price Target of $7
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight rating and announces Price Target of $7.
10-02 20:38
CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an update. On October 1...
10-01 20:48
JP Morgan Downgrades Camp4 Therapeutics to Neutral
JP Morgan analyst Anupam Rama downgrades Camp4 Therapeutics (NASDAQ:CAMP) from Overweight to Neutral.
09-16 18:41
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 239.0% to ...
09-10 20:11
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation announced it has secured up to $100 million in financing, with $50 million upfront and potential for an additional $50 million, to fund a Phase 1/2 clinical trial for SYNGAP1-related disorders, expected to begin by mid-2026. Doug Williams, Ph.D., was appointed Board Chair, and Dan Tardiff, Ph.D., became Chief Scientific Officer. The financing was led by Coastlands...
09-10 11:00
REGENXBIO Announces Data From Phase I/II/III CAMPSIITE Trial Of Clemidsogene Lanparvovec For Treatment Of Patients With Mucopolysaccharidosis Type II At ICIEM 2025
12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II>80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain disease, sustained
09-05 19:08
